1166 related articles for article (PubMed ID: 31088482)
21. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.
Byun HJ; Darvin P; Kang DY; Sp N; Joung YH; Park JH; Kim SJ; Yang YM
Oncol Rep; 2017 Jun; 37(6):3270-3278. PubMed ID: 28440514
[TBL] [Abstract][Full Text] [Related]
22. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
Jia LY; Shanmugam MK; Sethi G; Bishayee A
Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
[TBL] [Abstract][Full Text] [Related]
23. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
[TBL] [Abstract][Full Text] [Related]
26. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
27. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
Jiang F; Li Y; Si L; Zhang Z; Li Z
Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
[TBL] [Abstract][Full Text] [Related]
28. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
[TBL] [Abstract][Full Text] [Related]
29. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
30. Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3.
Dai X; Yin C; Guo G; Zhang Y; Zhao C; Qian J; Wang O; Zhang X; Liang G
Toxicol Appl Pharmacol; 2018 Nov; 358():110-119. PubMed ID: 30195018
[TBL] [Abstract][Full Text] [Related]
31. Novel Galiellalactone Analogues Can Target STAT3 Phosphorylation and Cause Apoptosis in Triple-Negative Breast Cancer.
Ko H; Lee JH; Kim HS; Kim T; Han YT; Suh YG; Chun J; Kim YS; Ahn KS
Biomolecules; 2019 May; 9(5):. PubMed ID: 31058868
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Wang S; Yao Y; Yao M; Fu P; Wang W
Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
[TBL] [Abstract][Full Text] [Related]
33. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J
BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346
[TBL] [Abstract][Full Text] [Related]
34. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.
James N; Owusu E; Rivera G; Bandyopadhyay D
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472
[TBL] [Abstract][Full Text] [Related]
35. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
36. Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.
Braicu C; Chiorean R; Irimie A; Chira S; Tomuleasa C; Neagoe E; Paradiso A; Achimas-Cadariu P; Lazar V; Berindan-Neagoe I
Expert Rev Mol Med; 2016 Nov; 18():e18. PubMed ID: 27817751
[TBL] [Abstract][Full Text] [Related]
37. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
Zhao H; Li D; Zhang B; Qi Y; Diao Y; Zhen Y; Shu X
Molecules; 2017 Dec; 22(12):. PubMed ID: 29261144
[TBL] [Abstract][Full Text] [Related]
38. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
40. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]